Assenagon Asset Management S.A. Sells 146,879 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Assenagon Asset Management S.A. lowered its position in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 14.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 905,184 shares of the company's stock after selling 146,879 shares during the quarter. Assenagon Asset Management S.A. owned 1.16% of Kura Oncology worth $7,884,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KURA. Harbor Capital Advisors Inc. raised its position in Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock worth $430,000 after acquiring an additional 2,076 shares during the period. JPMorgan Chase & Co. lifted its stake in Kura Oncology by 0.8% in the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock valued at $7,997,000 after purchasing an additional 3,092 shares during the last quarter. Franklin Resources Inc. grew its holdings in Kura Oncology by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after purchasing an additional 23,113 shares during the period. Geode Capital Management LLC increased its position in Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock worth $34,798,000 after buying an additional 41,535 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after buying an additional 84,563 shares during the period.

Kura Oncology Price Performance

Shares of KURA traded up $0.08 during trading hours on Monday, reaching $7.26. 1,174,495 shares of the company's stock traded hands, compared to its average volume of 1,533,541. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 12 month low of $6.98 and a 12 month high of $24.17. The stock has a market cap of $564.54 million, a PE ratio of -3.08 and a beta of 0.81. The firm's 50 day simple moving average is $10.51 and its 200-day simple moving average is $16.33.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on KURA shares. Wedbush reissued an "outperform" rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Monday, November 4th. Bank of America dropped their target price on Kura Oncology from $36.00 to $29.00 and set a "buy" rating on the stock in a research report on Friday, November 22nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a research note on Monday, December 9th. HC Wainwright increased their price objective on Kura Oncology from $32.00 to $37.00 and gave the stock a "buy" rating in a report on Thursday, November 21st. Finally, Stifel Nicolaus lowered Kura Oncology from a "buy" rating to a "hold" rating and reduced their target price for the company from $26.00 to $19.00 in a report on Monday, October 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $27.38.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.